Our library of drug research abstracts drawn from the medical literature is updated on a regular schedule, and you can be assured that new bricanyl research articles will be listed here shortly after becoming available to us.
Related Sponsors
Medical research on bricanyl
Nifedipine versus terbutaline for tocolysis in external cephalic version.
Int J Gynaecol Obstet. 2008 Jun 11;
Mohamed Ismail NA, Ibrahim M, Mohd Naim N, Mahdy ZA, Jamil MA, Mohd Razi ZR
OBJECTIVE: To study the efficacy of nifedipine compared with terbutaline as a tocolytic agent in external cephalic version (ECV). METHODS: A prospective, randomized, comparative trial was carried out in a tertiary hospital. Women with singleton term breech pregnancies were randomized for nifedipine (group A) and terbutaline (group B) tocolysis for ECV in an outpatient setting. The efficacy, side effects, and complications were analyzed and compared. RESULTS: A total of 86 women were recruited with 43 women in each group. The overall success rate was 48.8% and this reduced the rate of cesarean delivery for breech presentation by 32.5% in our center. ECV was successful in 39.5% of women in group A and 58.1% in group B. Fewer side effects were experienced by the women in group A compared with group B, although this was not significant. CONCLUSION: Nifedipine can be used as an alternative for tocolysis in ECV when there are maternal contraindications to beta-sympathomimetics.
J Hum Hypertens. 2008 Jun 12;
Lind L
Left ventricular hypertrophy (LVH) is a powerful cardiovascular risk factor and has previously been related to endothelium-dependent vasodilation (EDV) in hypertensive patients. In the Prospective Investigation of the Vasculature in Uppsala Seniors study, different techniques to evaluate EDV in different types of vessels were applied and were related to left ventricular mass index (LVMI) in the general population. In 1016 subjects aged 70 years, EDV was evaluated by the invasive forearm technique with acetylcholine given in the brachial artery, the brachial artery ultrasound technique with measurement of flow-mediated dilatation (FMD) and the pulse wave analysis method with beta-2-agonist (terbutaline) provocation. LVMI was determined by echocardiography. LVMI was related to both EDV and the pulse wave-based technique (both r=-0.14, P
Clin Physiol Funct Imaging. 2008 Jun 5;
Lind L
Background: Measurements of both arterial compliance and endothelium-dependent vasodilation have previously been related to coronary risk factors, but not in the same study. In the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study, we studied the interplay between arterial compliance and endothelium-dependent vasodilation on coronary risk. Methods: In the population-based PIVUS study (1016 subjects aged 70 years), arterial compliance was determined by ultrasound in the carotid artery, by pulse wave analysis (augmentation index) and the stroke volume to pulse pressure ratio by echocardiography, while endothelium-dependent vasodilation (EDV) was assessed by the invasive forearm technique with acetylcholine , brachial artery ultrasound [flow-mediated dilatation (FMD)] and pulse wave analysis with terbutaline provocation [change in reflection index (RI)]. Results: Factor analysis disclosed three major factors. The first factor was reflecting the three arterial compliance methods, the second factor was reflecting EDV and the change in RI, while the third factor mainly was reflecting FMD. All these three factors were independently related to the Framingham risk score in multiple regression analysis (P
J Aerosol Med Pulm Drug Deliv. 2008 Jun; 21(2): 169-80
Ewing P, Eirefelt SJ, Andersson P, Blomgren A, Ryrfeldt A, Gerde P
There is an increasing interest in using the lung as a route of entry for both local and systemic administration of drugs. However, because adequate technologies have been missing in the preclinical setting, few investigators have addressed the detailed disposition of drugs in the lung following short inhalation exposures to highly concentrated dry powder aerosols. New methods are needed to explore the disposition of drugs after short inhalation exposures, thus mimicking a future clinical use. Our aim was to study the pulmonary disposition of budesonide, formoterol, and terbutaline, which are clinically used for the treatment of bronchial asthma. Using the recently developed DustGun aerosol technology, we exposed by inhalation for approximately 1 min the isolated and perfused rat lung (IPL) to respirable dry particle aerosols of the three drugs at high concentrations. The typical aerosol concentration was 1 mug/mL, and the particle size distribution of the tested substances varied with a MMAD ranging from 2.3 to 5.3 mum. The IPL was perfused in single pass mode and repeated samples of the perfusate were taken for up to 80 min postexposure. The concentration of drug in perfusate and in lung extracts was measured using LC-MS/MS. The deposited dose was determined by adding the amounts of drug collected in perfusate to the amount extracted from the tissues at 80 min. Deposited amounts of budesonide, formoterol fumarate, and terbutaline sulphate were 23 +/- 17, 36 +/- 8, and 60 +/- 3.2 mug (mean +/- SD, n = 3), respectively. Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively. Each short inhalation exposure to the highly concentrated aerosols consumed 1-3 mg powder. Hence, this system can be particularly useful for obtaining a detailed pharmacokinetic characterization of inhaled compounds in drug discovery/development.
Can J Clin Pharmacol. 2008; 15(2): e165-76
Miller E, FitzGerald JM
OBJECTIVE: To compare the cost-effectiveness of budesonide/formoterol in a single inhaler used as Maintenance and Reliever Therapy (SMART) versus fixed higher-dose budesonide/formoterol plus as-needed terbutaline reliever (FHDBF) or fixed dose fluticasone/salmeterol plus as-needed terbutaline reliever (FDFS) in controlling asthma in adults and adolescents. METHODS: An economic evaluation was conducted by applying Canadian costs to the results of a large (N=3,335) international randomized, double-blind, controlled trial in which health resource utilization was prospectively collected. Although no Canadian subjects were enrolled in this clinical trial, it was assumed that the results would apply to Canadian patients. Primary outcome measurements included time to first exacerbation and the number of severe exacerbations. Costs included direct medical costs (physician/emergency room visits, hospitalizations, asthma drug costs) and productivity (absenteeism). The time horizon was six months, which corresponded to the duration of the trial. Prices were obtained from 2006 Canadian sources. Both healthcare and societal perspectives were considered. Deterministic univariate sensitivity analyses were conducted. RESULTS: In the clinical trial, SMART was superior to FHDBF and FDFS with respect to total number of severe exacerbations (RR 0.72; 95% CI 0.57, 0.90; p=0.0048; RR 0.61; 95% CI 0.49, 0.76; p
Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
Eur J Pharm Biopharm. 2008 Apr 11;
Thi TH, Danède F, Descamps M, Flament MP
Terbutaline sulphate particles, for use in dry powder inhaler formulations, were prepared by spray-drying, using a Büchi 190 mini spray dryer. Spray-drying conditions were chosen to allow the production of spray-dried terbutaline sulphate with a size similar to micronized terbutaline sulphate, that is to say about 2.9mum of volume mean diameter. The physical properties and in vitro inhalation behaviour of micronized and spray-dried terbutaline sulphate were compared. X-ray diffraction, DSC, SEM and laser size analysis were investigated. Spray-dying produced spherically shaped particles with amorphous structure. After blending with different lactoses, adhesion and aerodynamic properties were investigated. Evaluation of adhesion was carried out with a mechanical sieve and an Alpine air-jet sieve. The adhesion of terbutaline sulphate on the lactoses tested was lower in the case of the spray-dried drug. Aerodynamic evaluation of fine particle dose and emitted dose was conducted using a twin stage impactor. The emitted doses and the fine particle doses were higher with the spray-dried terbutaline sulphate. The Alpine air-jet sieve assays showed that there was a correlation between drug separation from a carrier by sieving and that obtained from longer in vitro deposition studies. There was a linear relationship between the adhesion characteristics and the fine particle dose.
Pediatr Pulmonol. 2008 Jul; 43(7): 627-33
Carroll CL, Schramm CM, Zucker AR
OBJECTIVES: While aerosolized administration of beta(2)-adrenergic receptor (beta(2)-AR) agonists is the mainstay of treatment for pediatric asthma exacerbations, the efficacy of intravenous (IV) delivery is controversial. Failure to demonstrate improved outcomes with IV beta(2)-AR agonists may be due to phenotypic differences within this patient population. Our hypothesis is that children who respond more slowly to IV beta(2)-AR agonist therapy comprise a distinct phenotype. METHODS: Retrospective chart review of all children admitted to the ICU for status asthmaticus who were treated with IV terbutaline between December 2002 and September 2006. RESULTS: Seventy-eight children were treated with IV terbutaline according to guidelines that adjusted the dose by clinical asthma score. After examining the histogram of duration of terbutaline infusions, a 48-hr cutoff was chosen to define responsiveness. Thirty-eight (49%) children were slow-responders by this definition. There were no significant differences in baseline asthma severity or severity on admission between the slow-responders and responders. Slow-responders required significantly higher total doses of IV terbutaline, higher maximum administration rates, and had longer ICU and hospital length of stay. CONCLUSION: There were significant differences in outcomes between the responders and slow-responders without differences in acute or chronic illness severity. Other factors may have lead to slower response to IV beta(2)-agonist therapy. Pediatr Pulmonol. 2008; 43:627-633. (c) 2008 Wiley-Liss, Inc.
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Apr; 28(4): 513-6
He L, Li TP, Zhu LH
OBJECTIVE: To observe the changes of the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in acutely isolated alveolar type II (ATII) cells from rats with acute respiratory distress syndrome (ARDS), and test the effects of terbutaline on the cAMP and cGMP levels. METHODS: SD rats were randomized into the control, ARDS, and terbutaline treatment groups, in which the cAMP and cGMP contents in the ATII cells were measured using radioimmunoassay, and the extravascular lung water (EVLW) content was quantified with gravimetric measurement. RESULTS: The cAMP level in the ATII cells was significantly lowered whereas cGMP level and EVLW content increased in rats with oleic acid-induced ARDS. In terbutaline-treated rats with ARDS, the EVLW content were lower than that of non-treated rats, but still higher than that of the control rats. Terbutaline treatment also increased the content of cAMP but produced no significant effect on cGMP content in the ATII cells of the rats with ARDS. CONCLUSION: Alveolar fluid clearance rate is decreased in rats with oleic acid-induced ARDS, and terbutaline can improve the capacity of alveolar fluid clearance, the mechanism of which may involve elevated cAMP content in the ATII cells. cAMP and cGMP in ATII cells might participate in the molecular pathogenesis of ARDS.
Acute tocolysis for uterine activity reduction in term labor a review.
Obstet Gynecol Surv. 2008 Jun; 63(6): 383-8; quiz 405
de Heus R, Mulder EJ, Derks JB, Visser GH
This review critically evaluates the efficacy of different tocolytics in reducing uterine pressure and contractions in term labor. The available evidence supports the use of beta-adrenergic-receptor agonists such as terbutaline or ritodrine; they appear to have an immediate and comparable profound effect on uterine activity in term labor. However, the preferred type of beta-adrenergic receptor agonist and dosage are unclear. The oxytocin receptor antagonist atosiban has a high specificity for the uterus with limited or no systemic effects and could therefore be an attractive alternative for use in term labor. The evidence on the tocolytic potency of a single bolus of atosiban for tocolysis in term labor is encouraging but limited and needs further research. Moreover, atosiban lacks United States Food and Drug Administration approval. Literature documenting efficacy and safety of nitroglycerin or magnesium sulfate in term labor is far from convincing. The theoretical basis for the use of tocolytics for nonreassuring intrapartum fetal heart rate patterns is to reduce the aggravating influence of uterine contractions. However, the clinical evidence that tocolytics in term active labor are actually beneficial in improving neonatal outcome is very limited.
J Food Prot. 2008 Apr; 71(4): 865-9
Lai WH, Fung DY, Xu Y, Xiong YH
Clenbuterol, which may cause symptoms of increased heart rate, muscular tremors, headache, nausea, and muscular cramps in patients, has been prohibited for consumption in many countries including the European Union, the United States, and China. A rapid lateral-flow strip assay was developed in our laboratory, and results obtained with this assay were compared with those obtained with a commercial enzyme-linked immunosorbent assay (ELISA) kit for the screening of clenbuterol in raw swine liver. A total of 128 swine livers were acquired from five local markets and prepared for analysis by the lateral-flow strip assay and ELISA. Analysis was completed in 10 min with the lateral-flow strip assay and in 90 min with the ELISA. In parallel with the ELISA, the rapid detection strip produced no false-negative results but had a false-positive rate of 6.3%. Cross-reactivity of the strip was assessed and was negative after tests with clenbuterol analogues such as terbutaline, salbutamol, ractopamine, ritodrine, and fenoterol. These data suggest that a lateral-flow strip assay can be used safely as a screening method as part of a clenbuterol residue surveillance program and should be a valuable tool in the food safety field, especially in developing countries.